UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis ...Middle East

With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases Approval in active PsA is supported by two Phase 3 studies in which BIMZELX showed...

Hence then, the article about ucb announces u s fda approvals for bimzelx bimekizumab bkzx for the treatment of psoriatic arthritis non radiographic axial spondyloarthritis and ankylosing spondylitis was published today ( Monday 23/09/2024 - 02:09 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis )

Also on site :

• Trump posts boastful Atlas-inspired Truth Social image of himself carrying the world on his shoulders
• Donald Trump Compares Young Photo of Himself to Teenage Barack Obama
• SoftBank’s CEO isn’t the only one with questions about Elon Musk’s orbital data center hype